Skip to main content

Advertisement

Table 1 Characteristics of the study population

From: Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study

  Total patients (n = 261) Patients followed up more than 1 year (n = 95)
Age (year) 57.1 ± 10.7 56.2 ± 10.3
F: M 170 (65.1): 91 (34.9) 64 (67.4): 31 (32.6)
*Follow-up duration (month) 21.6 ± 16.6 32.1 ± 13.9
Pulmonary function test
 FVC (%) 71.8 ± 18.4 72.5 ± 19.3
 FEV1 (%) 79.8 ± 20.9 81.1 ± 21.2
 DLco (%) 64.9 ± 21.3 64.7 ± 22.5
*Resting PaO2 mm Hg 81.6 ± 17.3 86.7 ± 14.8
Smoking status
 Never smoker 169/241 (70.1) 68/92 (73.9)
 Ex-smoker 38/241 (15.8) 16/92 (17.4)
 current smoker 34/241 (14.1) 8/92 (8.7)
*Smoking amount (Pys) 29.3 ± 16.8 29.0 ± 15.2
Initial symptom
 Dyspnea of exertion 179/230 (77.8) 64/80 (80.0)
 Cough 159/219 (72.6) 55/81 (67.9)
 Sputum 69/186 (37.1) 28/71 (39.4)
*Duration of symptom (month) 6.2 ± 10.2 7.1 ± 12.0
*CRP (mg/dL) 2.52 ± 6.21 1.56 ± 3.68
ANA (positive) 58/185 (31.4) 18/59 (30.5)
RF (positive) 28/173 (16.2) 11/59 (18.6)
Outcome
 Alive 157/261 (60.2) 73/95 (76.8)
 Death 26/261 (10.0) 3/95 (3.2)
 Follow-up loss 78/261 (29.9) 19/95 (20.0)
  1. Note: Values in parentheses are percentages
  2. F:M female:male, FVC, forced vital capacity, % pred percentage of the predicted value, FEV 1 forced expiratory volume, DL CO diffusing capacity of the lung for carbon monoxide, PaO 2 arterial oxygen tension, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor
  3. *Follow-up duration, smoking amount, duration of symptoms, and CRP showed a non-normal distribution in all patients
  4. *Resting PaO2 mm Hg, duration of symptom, and CRP showed a non-normal distribution in patients followed up for more than 1 year